0001104659-23-023307.txt : 20230217 0001104659-23-023307.hdr.sgml : 20230217 20230217163220 ACCESSION NUMBER: 0001104659-23-023307 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20230217 DATE AS OF CHANGE: 20230217 EFFECTIVENESS DATE: 20230217 FILER: COMPANY DATA: COMPANY CONFORMED NAME: KIORA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001372514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-473810 FILM NUMBER: 23643172 BUSINESS ADDRESS: STREET 1: 332 ENCINITAS BOULEVARD STREET 2: SUITE 102 CITY: ENCINITAS STATE: CA ZIP: 92024 BUSINESS PHONE: 781-788-8869 MAIL ADDRESS: STREET 1: 332 ENCINITAS BOULEVARD STREET 2: SUITE 102 CITY: ENCINITAS STATE: CA ZIP: 92024 FORMER COMPANY: FORMER CONFORMED NAME: EYEGATE PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060811 D 1 primary_doc.xml X0708 D LIVE 0001372514 KIORA PHARMACEUTICALS INC 332 ENCINITAS BOULEVARD SUITE 102 ENCINITAS CA CALIFORNIA 92024 781-788-9043 DELAWARE None EYEGATE PHARMACEUTICALS INC Corporation true Brian Strem 332 Encinitas Blvd, Suite 102 Encinitas CA CALIFORNIA 92024 Executive Officer Director President and Chief Executive Officer Melissa Tosca 332 Encinitas Blvd, Suite 102 Encinitas CA CALIFORNIA 92024 Executive Officer Executive VP of Finance Eric Daniels 332 Encinitas Blvd, Suite 102 Encinitas CA CALIFORNIA 92024 Executive Officer Chief Development Officer Paul Chaney 332 Encinitas Blvd, Suite 102 Encinitas CA CALIFORNIA 92024 Director Aron Shapiro 332 Encinitas Blvd, Suite 102 Encinitas CA CALIFORNIA 92024 Director Kenneth Gayron 332 Encinitas Blvd, Suite 102 Encinitas CA CALIFORNIA 92024 Director Praveen Tyle 332 Encinitas Blvd, Suite 102 Encinitas CA CALIFORNIA 92024 Director David Hollander 332 Encinitas Blvd, Suite 102 Encinitas CA CALIFORNIA 92024 Director Erin Parsons 332 Encinitas Blvd, Suite 102 Encinitas CA CALIFORNIA 92024 Director Pharmaceuticals Decline to Disclose 06b false 2023-02-03 false true true true false 0 200000 200000 0 Total Offering Amount represents up to $10,000,000 of common stock that may be issued in the future pursuant to a Purchase Agreement between the issuer and the investor. See the issuer's Current Report on Form 8-K filed on February 3, 2023. false 1 0 0 0 Some of the proceeds may be used for working capital and other general corporate purposes, which may include the payment of salaries and other fees to those listed in Item 3. false KIORA PHARMACEUTICALS INC /s/ Melissa Tosca Melissa Tosca EVP of Finance 2023-02-17